Moderna Q2 FY26 net loss narrows 5% to $0.8 billion; revenue rises to $145 million

Reuters2026/07/31 11:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moderna posted Q2 revenue of USD 145 million, up 2.11% year over year, on lower U.S. and South America COVID sales.
GAAP net loss narrowed 5% to USD 0.8 billion; GAAP loss per share improved to USD 1.97.
GAAP cost of sales fell 22% to USD 93 million, including USD 41 million of inventory write-downs and USD 23 million of unutilized capacity costs.
R&D expenses slipped 7% to USD 651 million; SG&A declined 6% to USD 216 million as the company cited continued discipline.
Moderna reiterated up to 10% 2026 revenue growth, flagged an Aug. 5 PDUFA date for mFLUSIVA, and said its Phase 3 norovirus interim analysis missed early success criteria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607310700ACCESSWRNAPR_____1199078) on July 31, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moderna Q2 FY26 net loss narrows 5% to $0.8 billion; revenue rises to $145 million

You may also like

Crypto prices